Lupus (SLE) stem cell therapy — your questions answered (2026)
About stem cell therapy for Lupus (SLE)
Systemic lupus erythematosus is a heterogeneous autoimmune disease that may affect skin, joints, blood, kidneys, nervous system and other organs. MSCs, haematopoietic transplantation and engineered immune-cell approaches have different aims and risks. They must not be grouped as one stem-cell treatment or described as universally resetting immunity.
The evidence for Lupus (SLE)
Standard care is tailored to organ involvement and may include antimalarial, immunosuppressive, biologic and supportive treatment. HSCT and newer cellular immune approaches have been studied mainly in selected severe or refractory disease and can involve substantial toxicity. MSC evidence remains investigational and heterogeneous. The NIAMS lupus treatment guide should be used to compare established care; evidence from one cellular platform cannot validate another.
Itemise exact diagnosis and organ assessment, product, conditioning or immunosuppression where applicable, admission, infection prevention, fertility issues, travel, long-term follow-up and complications. Do not stop effective lupus treatment or delay kidney, neurological or cardiovascular care for a commercial infusion.
Can stem cells treat lupus?
Cell therapy for Lupus (SLE) may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.
Which lupus patients qualify?
Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.
Is it a transplant?
Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.
EU cost?
The partner-published indicative range for an Lupus (SLE) programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Lupus (SLE) (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗